ArticleDie Naturwissenschaften2026
Cardiovascular effects of Matricaria chamomilla extract: calcium channel modulation and vasorelaxant activity.
Article in Die Naturwissenschaften, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the vasorelaxant potential of M. chamomilla extract and its modulatory effects on calcium ion channels.In vitro experiments assessed the extract’s impact on voltage-gated and GPCR-mediated calcium channels in aortic preparations. In vivo, the Tail Cuff method evaluated blood pressure-lowering effects in adrenaline-induced hypertensive rats. Phytochemical profiling was performed via GC-MS, and molecular docking assessed interactions of key compounds with vascular regulation targets (7VFS, 8THK, 3NOS). In vitro, 5 µg/ mL of the extract slightly increased aortic contractility (3.9 ± 3.4%), whereas 60 µg/ mL markedly reduced it (89.5 ± 3.1%). At 50 µg/ mL, it inhibited phenylephrine-induced GPCR-mediated contractions by 84.9 ± 3.8%. In vivo, 40 mg/kg of the extract lowered systolic and diastolic pressures to 150 mmHg and 110 mmHg, respectively. GC-MS identified pinocarveol, coumarin, apigenin derivatives, and dicaffeoylquinic acids. Molecular docking revealed strong affinities of apigenin-7-O-neohesperidoside and other compounds to key vascular targets. Both experimental approaches consistently demonstrated vasorelaxant activity, likely linked to polyphenol and flavonoid content. M. chamomilla extract exhibits significant vasorelaxant and antihypertensive effects, mediated through modulation of calcium channels and bioactive polyphenols. These findings support its potential as a therapeutic agent for hypertension and hypoxia-related cardiovascular disorders, warranting further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.